12:30 PM EST, 01/10/2025 (MT Newswires) -- Rein Therapeutics (ALRN), formerly Aileron Therapeutics ( ALRN ), said Friday that it changed names to reflect its focus on developing first-in-class treatments for rare pulmonary and fibrosis diseases.

The company's stock will begin trading under the new Nasdaq ticker "RNTX" on Monday, it added.

The company also said its key goals for 2025 include initiating a phase 2 trial of LTI-03 for the treatment of idiopathic pulmonary fibrosis in H1.

Shares of the company rose 4.7% in recent trading activity.

Price: 2.02, Change: +0.09, Percent Change: +4.66